Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis
- 9 July 2016
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 14 (12), 1821-1830.e6
- https://doi.org/10.1016/j.cgh.2016.07.001
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)Hepatology, 2016
- Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin useJournal of Hepatology, 2015
- Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced CirrhosisDigestive Diseases and Sciences, 2014
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisThe New England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionThe New England Journal of Medicine, 2014
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010